Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Open accessThe DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index.
Abstract
Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 target agents by the U.S. Food and Drug Administration. This review summarizes the most significant and updated research on clinical scenarios related to HER2-positive breast cancer management in order to revise the guidelines of everyday clinical practices. In this article, we present the data on anti-HER2 clinical research of neoadjuvant, adjuvant, and metastatic studies from the past 2 decades. We also highlight some of the promising strategies that should be critically considered. Lastly, this review lists some of the ongoing clinical trials, findings of which may soon be available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–275 of 275
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p1-14-20 · Cited by 78
Watanabe, S., Yonesaka, K., Tanizaki, J., Nonagase, Y., Takegawa, N., Haratani, K., Kawakami, H., Hayashi, H., Takeda, M., Tsurutani, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1995 · Cited by 78
Hurvitz, S. A., Dalenc, F., Campone, M., O’Regan, R. M., Tjan-Heijnen, V. C., Gligorov, J., Llombart, A., Jhangiani, H., Mirshahidi, H. R., Tan-Chiu, E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2689-5 · Cited by 76
von Minckwitz, G., Rezai, M., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., Hanusch, C. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt410 · Cited by 75
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., Laurentiis, M. D., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1088 · Cited by 74
Denkert, C., Huober, J., Loibl, S., Prinzler, J., Kronenwett, R., Darb‐Esfahani, S., Brase, J. C., Solbach, C., Mehta, K. M., Fasching, P. A., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3384 · Cited by 69
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study
Pivot, X. B., Suter, T. M., Nabholtz, J. M., Pierga, J., Espié, M., Lortholary, A. H., Khayat, D., Pauporté, I., Romieu, G., Kramar, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.028 · Cited by 69
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review
Chellappan, D. K., Chellian, J., Ng, Z. Y., Sim, Y. J., Theng, C. W., Ling, J., Wong, M., Foo, J. H., Yang, G. J., Hang, L., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.058 · Cited by 67
McCullough, A. E., Dell’Orto, P., Reinholz, M. M., Gelber, R. D., Dueck, A. C., Russo, L., Jenkins, R. B., Andrighetto, S., Chen, B., Jackisch, C., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2827-0 · Cited by 66
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin
Dawood, S. S., Gonzalez-Angulo, A. M., Peintinger, F., Broglio, K. R., Symmans, W. F., Kau, S., Islam, R., Hortobágyi, G. N., & Buzdar, A. U. (2007) · Cancer · doi:10.1002/cncr.22895 · Cited by 65
Park, Y. H., Kim, S. T., Cho, E. Y., Choi, Y., Ok, O.-N., Baek, H. J., Lee, J. E., Nam, S. J., Yang, J., Park, W., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0665-x · Cited by 65
Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M. A., Ottmann, O. G., Ruf, P., Lindhofer, H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2449-0 · Cited by 65
Ponde, N. F., Bradbury, I., Lambertini, M., Ewer, M. S., Campbell, C., Ameels, H., Zardavas, D., Cosimo, S. D., Baselga, J. M., Huober, J., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4628-3 · Cited by 65
Sakai, H., Tsurutani, J., Iwasa, T., Komoike, Y., Sakai, K., Nishio, K., & Nakagawa, K. (2018) · Breast Cancer · doi:10.1007/s12282-018-0861-9 · Cited by 65
Quantitative PCR and HER2 Testing in Breast Cancer
Barberis, M. C. P., Pellegrini, C., Cannone, M., Arizzi, C., Coggi, G., & Bòsari, S. (2008) · American Journal of Clinical Pathology · doi:10.1309/1akqdq057pqt9akx · Cited by 64
Yu, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90277-5 · Cited by 62
Hudelist, G., Köstler, W. J., Attems, J., Czerwenka, K. F., Müller, R., Manavi, M., Steger, G. G., Kubista, E., Zielinski, C. C., & Singer, C. F. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601160 · Cited by 62
Stemmler, H., & Heinemann, V. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0052 · Cited by 60
Molecular signature detection of circulating tumor cells using a panel of selected genes
Gervasoni, A., Muñoz, R. M. M., Wengler, G. S., Rizzi, A., Zaniboni, A., & Parolini, O. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.01.003 · Cited by 59
Baron, J. M., Boster, B. L., & Barnett, C. M. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214527144 · Cited by 59
THE ROLE OF CHEMOTHERAPY FOR METASTATIC BREAST CANCER
Miller, K. D., & Sledge, G. W. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70063-0 · Cited by 58
Raja, S. M., Luan, H., Naramura, M., Bailey, T., Clubb, R. J., Band, V., & Band, H. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.90442 · Cited by 58
STAT 3 activation confers trastuzumab‐emtansine (T‐ DM 1) resistance in HER 2‐positive breast cancer
Wang, L., Wang, Q., Gao, M., Li, F., Li, Y., Quan, H., & Lou, L. (2018) · Cancer Science · doi:10.1111/cas.13761 · Cited by 58
Ertumaxomab: a trifunctional antibody for breast cancer treatment
Kiewe, P. M., & Thiel, E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1553 · Cited by 56
Chibon, F., de Mascarel, I., Sierankowski, G., Brouste, V., Bonnefoi, H. R., Debled, M., Mauriac, L., & MacGrogan, G. M. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.195 · Cited by 56
Costa, R. L. B., Soliman, H. H., & Czerniecki, B. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.005 · Cited by 56
Kowalczyk, L., Bartsch, R., Singer, C. F., & Farr, A. (2017) · Breast Care · doi:10.1159/000480492 · Cited by 55
Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients
Ahmad, S., Gupta, S., Kumar, R., Varshney, G. C., & Raghava, G. P. S. (2014) · Scientific Reports · doi:10.1038/srep04483 · Cited by 54
Millson, A., Suli, A., Hartung, L., Kunitake, S., Bennett, A., Nordberg, M. C. L., Hanna, W., Wittwer, C. T., Seth, A., & Lyon, E. (2003) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60471-0 · Cited by 51
Peintinger, F., Buzdar, A. U., Kuerer, H. M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn427 · Cited by 49
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M. D., Guardino, E., Althaus, B., Lu, D., Strasak, A. M., & ELIAS, A. D. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0691-7 · Cited by 49
Diaby, V., Adunlin, G., Ali, A. A., Zeichner, S. B., Lopes, G. D. L., Jr., Kohn, C. G., & Montero, A. J. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3978-6 · Cited by 49
Afatinib in the treatment of breast cancer
Hurvitz, S. A., Shatsky, R. A., & Harbeck, N. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.924505 · Cited by 48
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
Zhang, K., Hong, R., Lee, K., Xu, F., Xia, W., Qin, G., Zheng, Q., Lu, Q., Zhai, Q., Shi, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.005 · Cited by 48
Sawaki, M., Ito, Y., Tada, K., Mizunuma, N., Takahashi, S., Horikoshi, N., Kasumi, F., Akiyama, F., Sakamoto, G., Imai, T., et al. (2004) · Tumori Journal · doi:10.1177/030089160409000110 · Cited by 42
Rimawi, M. F., Aleixo, S. B., Alarcon-Rozas, A. E., Neto, J. N. D. M., Caleffi, M. M., Figueira, A. C., Souza, S. C., Reiriz, A. B., Gutiérrez, C., Arantes, H., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.11.004 · Cited by 42
Montemurro, F., Prat, A., Rossi, V., Valabrega, G., Sperinde, J., Neia, C. P., Donadio, M., Galván, P., Sapino, A., Aglietta, M., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.013 · Cited by 41
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
Chan, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016656494 · Cited by 41
Koopman, T., Buikema, H. J., Hollema, H., de Bock, G. H., & van der Vegt, B. (2018) · Histopathology · doi:10.1111/his.13812 · Cited by 40
Treatment and Survival Outcome for Molecular Breast Cancer Subtypes in Black Women
Ihemelandu, C. U., Naab, T. J., Mezghebe, H. M., Makambi, K. H., Siram, S. M., Leffall, L. D., DeWitty, R. L., & Frederick, W. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815d744a · Cited by 39
Choi, H. D., & Chang, M. J. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4460-9 · Cited by 39
Debiasi, M., Polanczyk, C. A., Ziegelmann, P. K., Barrios, C. H., Cao, H., Dignam, J. J., Goss, P. E., Bychkovsky, B., Finkelstein, D. M., Guindalini, R. S. C., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00156 · Cited by 39
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
Brandão, M., Ponde, N. F., Poggio, F. B., Kotecki, N., Salis, M., Lambertini, M., & de Azambuja, E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1477596 · Cited by 37
HER2 overexpressing metastatic breast cancer
Spigel, D. R., & Burstein, H. J. (2002) · Current Treatment Options in Oncology · doi:10.1007/s11864-002-0062-8 · Cited by 36
Conte, P., Bisagni, G., Frassoldati, A., Brandes, A. A., Anselmi, E., Giotta, F., Aieta, M., Gebbia, V., Musolino, A., Garrone, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.501 · Cited by 36
Goh, G., Schmid, R., Guiver, K., Arpornwirat, W., Chitapanarux, I., Ganju, V., Im, S., Kim, S., Dechaphunkul, A., Maneechavakajorn, J., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002136 · Cited by 35
A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
Yang, L., Li, Y., Bhattacharya, A., & Zhang, Y. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1620 · Cited by 35
Metzger, O., de Azambuja, E., Bradbury, I., Saini, K. S., Bines, J., Simon, S. D., Dooren, V. V., Aktan, G., Pritchard, K. I., Wolff, A. C., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0342 · Cited by 34
Self-citationÇetin, B., Beneklı, M., Türker, İ., Koral, L., Ulaş, A., Dane, F., Öksüzoğlu, B. Ç., Ma, K., Koca, D., Boruban, C. M., et al. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000147 · Cited by 33
Ma, K., Işıkdoğan, A., Koca, D., Küçüköner, M., Gümüşay, Ö., Yıldız, R., Dayan, A., Demir, L., Geredeli, Ç., Koçer, M., et al. (2013) · Breast Cancer · doi:10.1007/s12282-013-0441-y · Cited by 32
Yaziji, H., & Gown, A. M. (2002) · Advances in Anatomic Pathology · doi:10.1097/00125480-200211000-00002 · Cited by 32
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
Leo, A. D. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8951 · Cited by 31
Pyrotinib shows activity in metastatic breast cancer
Gourd, E. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30755-6 · Cited by 30
Blackwell, K., Zaman, K., Qin, S., Tkaczuk, K. H. R., Campone, M., Hunt, D., Bryce, R. P., & Goldstein, L. J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.12.011 · Cited by 30
Keup, C., Storbeck, M., Hauch, S., Hahn, P. F., Sprenger‐Haussels, M., Tewes, M., Mach, P., Hoffmann, O., Kimmig, R., & Kasimir‐Bauer, S. (2019) · Cancers · doi:10.3390/cancers11020238 · Cited by 30
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Advani, P. P., Cornell, L. F., Chumsri, S., & Moreno‐Aspitia, A. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s90627 · Cited by 29
Neratinib for the treatment of HER2-positive early stage breast cancer
Echavarría, I., López‐Tarruella, S., Márquez‐Rodas, I., Jerez, Y., & Martín, M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1338954 · Cited by 29
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
Guiu, S., Mouret‐Reynier, M., Touré, M., & Coudert, B. P. (2013) · Journal of Oncology · doi:10.1155/2013/854121 · Cited by 26
Burstein, H. J., & Winer, E. P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2222 · Cited by 26
Lee, J., Franovic, A., Shiotsu, Y., Kim, S. T., Kim, K.-M., Banks, K. C., Raymond, V. M., & Lanman, R. B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00212 · Cited by 25
Nishimura, R., Toh, U., Tanaka, M., Saimura, M., Okumura, Y., Saito, T., Tanaka, T., Teraoka, M., Shimada, K., Katayama, K., et al. (2017) · Oncology · doi:10.1159/000468521 · Cited by 24
Dokmanovic, M., King, K. E., Mohan, N., Endo, Y., & Wu, W. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1337746 · Cited by 24
Okines, A. F. C., Irfan, T., Khabra, K., Smith, I., O'Brien, M. E. R., Parton, M., Noble, J., Stanway, S., Somaiah, N., Ring, A. E., et al. (2017) · The Breast Journal · doi:10.1111/tbj.12906 · Cited by 24
Shawky, H., & Tawfik, H. A. (2014) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2014.08.001 · Cited by 21
Fontanella, C., Carlo, E. D., Cinausero, M., Pelizzari, G., Venuti, I., & Puglisi, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.014 · Cited by 21
Tervonen, H. E., Daniels, B. J., Tang, M., Preen, D. B., & Pearson, S. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4751 · Cited by 18
Costa, R. L. B., Zaman, S., Sharpe, S. C., Helenowski, I., Shaw, C., Han, H. S., Soliman, H. H., & Czerniecki, B. J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s188925 · Cited by 17
Diermeier‐Daucher, S., Ortmann, O., Buchholz, S., & Brockhoff, G. (2012) · mAbs · doi:10.4161/mabs.21003 · Cited by 16
Curran, M. P. (2010) · Drugs · doi:10.2165/11204550-000000000-00000 · Cited by 14
Gao, W., Wu, J., Chen, X., Lin, L., Fei, X., Shen, K., & Huang, O. (2019) · Journal of Cancer · doi:10.7150/jca.29337 · Cited by 12
Kirschbrown, W. P., Kågedal, M., Wang, B., Lindbom, L., Knott, A., Mack, R., Monemi, S., Nijem, I., Girish, S., Freeman, C., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03826-1 · Cited by 10
Pivot, X. B., Fumoleau, P., Pierga, J., Delaloge, S., Bonnefoi, H. R., Bachelot, T., Jouannaud, C., Bourgeois, H. P., Rios, M., Soulié, P., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.020 · Cited by 5
Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients
Watanuki, R., Hayashida, T., Kawai, Y., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01420-2 · Cited by 5
Bates, G. J., Bignone, P. A., & Banham, A. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2696 · Cited by 4
Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.
Jia, W., & Wang, T. Z. (2019) · PubMed · Cited by 1
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
“As reported in Her2+ breast cancer patients treated with Trastuzumab and chemotherapy, the treatment-induced epitope spreading was characterized by increased antibody responses not only to the tumor antigen Her2, but also to endogenous CEA, insulin-like growth factor-binding protein 2 (IGFBP2), and p53 (521).”
BackgroundInfluentialBreast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
van der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202100639 · Cited by 418
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
Andersson, A., Larsson, L., Stenbeck, L., Salmén, F., Ehinger, A., Wu, S. Z., Al-Eryani, G., Roden, D., Swarbrick, A., Borg, Å., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26271-2 · Cited by 404
Metadata
- Authors
- Wang, J., & Xu, B.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2019-09-13
- Volume
- 4
- Issue
- 1
- Pages
- 34-34
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W2972399366
- Cited by
- 393
- References
- 275
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.